The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status

被引：102

作者：

Green, Claire L. ^{[1
]}

Evans, Catherine M. ^{[1
]}

Hills, Robert K. ^{[2
]}

Burnett, Alan K. ^{[2
]}

Linch, David C. ^{[1
]}

Gale, Rosemary E. ^{[1
]}

机构：

[1] UCL Canc Inst, Dept Haematol, London WC1E 6DD, England

[2] Cardiff Univ Sch Med, Dept Haematol, Cardiff, S Glam, Wales

来源：

BLOOD | 2010年 / 116卷 / 15期

基金：

英国医学研究理事会;

关键词：

DISTINCT; IMPACT; AML;

D O I：

10.1182/blood-2010-02-270926

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Mutations in the isocitrate dehydrogenase gene (IDH1) were recently described in patients with acute myeloid leukemia (AML). To investigate their prognostic significance we determined IDH1 status in 1333 young adult patients, excluding acute promyelocytic leukemia, treated in the United Kingdom MRC AML10 and 12 trials. A mutation was detected in 107 patients (8%). Most IDH1(+) patients (91%) had intermediate-risk cytogenetics. Mutations correlated significantly with an NPM1 mutation (P < .0001) but not a FLT3/ITD (P = .9). No difference in outcome between IDH1(+) and IDH1(-) patients was found in univariate or multivariate analysis, or if the results were stratified by NPM1 mutation status. However, when stratified by FLT3/ITD status, an IDH1 mutation was an independent adverse factor for relapse in FLT3/ITD- patients (P = .008) and a favorable factor in FLT3/ITD+ patients (P = .02). These results suggest that metabolic changes induced by an IDH1 mutation may influence chemoresistance in a manner that is context-dependent. (Blood. 2010;116(15): 2779-2782)

引用

页码：2779 / 2782

页数：4

共 19 条

[1] Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value [J].

Abbas, Saman ;

Lugthart, Sanne ;

Kavelaars, Francois G. ;

Schelen, Anita ;

Koenders, Jasper E. ;

Zeilemaker, Annelieke ;

van Putten, Wim J. L. ;

Rijneveld, Anita W. ;

Lowenberg, Bob ;

Valk, Peter J. M. .

BLOOD, 2010, 116 (12) :2122-2126

[2] Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation [J].

Chou, Wen-Chien ;

Hou, Hsin-An ;

Chen, Chien-Yuan ;

Tang, Jih-Luh ;

Yao, Ming ;

Tsay, Woei ;

Ko, Bor-Shen ;

Wu, Shang-Ju ;

Huang, Shang-Yi ;

Hsu, Szu-Chun ;

Chen, Yao-Chang ;

Huang, Yen-Ning ;

Chang, Yi-Chang ;

Lee, Fen-Yu ;

Liu, Ming-Chi ;

Liu, Chia-Wen ;

Tseng, Mei-Hsuan ;

Huang, Chi-Fei ;

Tien, Hwei-Fang .

BLOOD, 2010, 115 (14) :2749-2754

[3] Cancer-associated IDH1 mutations produce 2-hydroxyglutarate [J].

Dang, Lenny ;

White, David W. ;

Gross, Stefan ;

Bennett, Bryson D. ;

Bittinger, Mark A. ;

Driggers, Edward M. ;

Fantin, Valeria R. ;

Jang, Hyun Gyung ;

Jin, Shengfang ;

Keenan, Marie C. ;

Marks, Kevin M. ;

Prins, Robert M. ;

Ward, Patrick S. ;

Yen, Katharine E. ;

Liau, Linda M. ;

Rabinowitz, Joshua D. ;

Cantley, Lewis C. ;

Thompson, Craig B. ;

Heiden, Matthew G. Vander ;

Su, Shinsan M. .

NATURE, 2009, 462 (7274) :739-U52

[4] Molecular characterization of acute myeloid leukemia [J].

Doehner, Konstanze ;

Doehner, Hartmut .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (07) :976-982

[5] The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia [J].

Gale, Rosemary E. ;

Green, Claire ;

Allen, Christopher ;

Mead, Adam J. ;

Burnett, Alan K. ;

Hils, Robert K. ;

Linch, David C. .

BLOOD, 2008, 111 (05) :2776-2784

[6] Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations [J].

Green, Claire L. ;

Koo, Kenneth K. ;

Hills, Robert K. ;

Burnett, Alan K. ;

Linch, David C. ;

Gale, Rosemary E. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) :2739-2747

[7] The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].

Grimwade, D ;

Walker, H ;

Oliver, F ;

Wheatley, K ;

Harrison, C ;

Harrison, G ;

Rees, J ;

Hann, I ;

Stevens, R ;

Burnett, A ;

Goldstone, A .

BLOOD, 1998, 92 (07) :2322-2333

[8] Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study [J].

Ho, P. A. ;

Alonzo, T. A. ;

Kopecky, K. J. ;

Miller, K. L. ;

Kuhn, J. ;

Zeng, R. ;

Gerbing, R. B. ;

Raimondi, S. C. ;

Hirsch, B. A. ;

Oehler, V. ;

Hurwitz, C. A. ;

Franklin, J. L. ;

Gamis, A. S. ;

Petersdorf, S. H. ;

Anderson, J. E. ;

Reaman, G. H. ;

Baker, L. H. ;

Willman, C. L. ;

Bernstein, I. D. ;

Radich, J. P. ;

Appelbaum, F. R. ;

Stirewalt, D. L. ;

Meshinchi, S. .

LEUKEMIA, 2010, 24 (05) :909-913

[9] Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers [J].

Kang, Mi Ran ;

Kim, Min Sung ;

Oh, Ji Eun ;

Kim, Yoo Ri ;

Song, Sang Yong ;

Seo, Seong Il ;

Lee, Ji Youl ;

Yon, Nam Jin ;

Lee, Sug Hyung .

INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (02) :353-355

[10] IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study [J].

Marcucci, Guido ;

Maharry, Kati ;

Wu, Yue-Zhong ;

Radmacher, Michael D. ;

Mrozek, Krzysztof ;

Margeson, Dean ;

Holland, Kelsi B. ;

Whitman, Susan P. ;

Becker, Heiko ;

Schwind, Sebastian ;

Metzeler, Klaus H. ;

Powell, Bayard L. ;

Carter, Thomas H. ;

Kolitz, Jonathan E. ;

Wetzler, Meir ;

Carroll, Andrew J. ;

Baer, Maria R. ;

Caligiuri, Michael A. ;

Larson, Richard A. ;

Bloomfield, Clara D. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (14) :2348-2355

← 1 2 →